• LAST PRICE
    31.0600
  • TODAY'S CHANGE (%)
    Trending Up0.8600 (2.8477%)
  • Bid / Lots
    15.3300/ 2
  • Ask / Lots
    33.7100/ 5
  • Open / Previous Close
    30.6000 / 30.2000
  • Day Range
    Low 30.3339
    High 31.0600
  • 52 Week Range
    Low 14.3300
    High 33.7800
  • Volume
    55,185
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 30.2
TimeVolumeXOMA
09:32 ET25530.6
09:39 ET30030.4854
09:50 ET205230.9504
10:02 ET28930.44
10:22 ET30030.6
10:33 ET10030.7
10:44 ET60030.85
10:47 ET10030.7
11:23 ET10030.7
11:25 ET10030.55
11:27 ET10030.575
11:30 ET50030.5
11:38 ET10030.5
11:48 ET10030.5
12:10 ET10030.5
12:19 ET10030.5
01:06 ET60030.6
01:15 ET60030.7
01:18 ET20030.7
01:20 ET10030.595
01:31 ET10030.7
01:54 ET20030.7
02:02 ET20030.73
02:03 ET10030.735
02:23 ET10030.6957
03:12 ET52530.61
03:14 ET33830.675
03:15 ET10030.555
03:17 ET1892530.85
03:19 ET66430.85
03:24 ET80030.53
03:30 ET60030.7
03:35 ET10030.66
03:42 ET20030.7
03:46 ET20030.57
03:51 ET10030.55
04:00 ET590731.06
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesXOMA
XOMA Royalty Corp
355.8M
-10.1x
---
United StatesNWBO
Northwest Biotherapeutics Inc
352.3M
-4.2x
---
United StatesENGN
enGene Holdings Inc
339.6M
-1.7x
---
United StatesJSPR
Jasper Therapeutics Inc
330.8M
-4.8x
---
United StatesPRME
Prime Medicine Inc
384.1M
-1.6x
---
United StatesKOD
Kodiak Sciences Inc
325.7M
-1.8x
---
As of 2024-11-25

Company Information

XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, mezagitamab (TAK-079), acimtamig (AFM13), AB054, ficlatuzumab (AV-299), COM902, vosaroxin, aldoxorubicin, INCAGN02385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], CMP-001 (vidutolimod), NTM-1631, NTM-1634, NTM-1633, NTM-1632, NIR178, MK-4830, AFM24, INCAGN01949, AB101, and CFZ533 (iscalimab).

Contact Information

Headquarters
2200 Powell Street, Suite 310EMERYVILLE, CA, United States 94608
Phone
510-204-7239
Fax
302-655-5049

Executives

Independent Chairman of the Board
Jack Wyszomierski
Chief Executive Officer, Director
Owen Hughes
Chief Financial Officer, Senior Vice President - Finance
Thomas Burns
Chief Investment Officer
Bradley Sitko
Independent Director
Heather Franklin

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$355.8M
Revenue (TTM)
$21.6M
Shares Outstanding
11.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.86
EPS
$-3.06
Book Value
$7.72
P/E Ratio
-10.1x
Price/Sales (TTM)
16.5
Price/Cash Flow (TTM)
---
Operating Margin
-154.31%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.